Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $16.8 million.

  • Orthopediatrics' Cash & Equivalents fell 6703.82% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year decrease of 6703.82%. This contributed to the annual value of $43.8 million for FY2024, which is 4110.45% up from last year.
  • As of Q3 2025, Orthopediatrics' Cash & Equivalents stood at $16.8 million, which was down 6703.82% from $44.6 million recorded in Q2 2025.
  • In the past 5 years, Orthopediatrics' Cash & Equivalents registered a high of $51.0 million during Q3 2024, and its lowest value of $6.3 million during Q3 2021.
  • In the last 5 years, Orthopediatrics' Cash & Equivalents had a median value of $21.5 million in 2021 and averaged $24.2 million.
  • In the last 5 years, Orthopediatrics' Cash & Equivalents tumbled by 9283.26% in 2021 and then soared by 37976.5% in 2024.
  • Orthopediatrics' Cash & Equivalents (Quarter) stood at $7.6 million in 2021, then increased by 17.67% to $9.0 million in 2022, then surged by 245.4% to $31.1 million in 2023, then surged by 41.1% to $43.8 million in 2024, then plummeted by 61.6% to $16.8 million in 2025.
  • Its Cash & Equivalents was $16.8 million in Q3 2025, compared to $44.6 million in Q2 2025 and $33.4 million in Q1 2025.